Study to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in the pre-surgical treatment of triple-negative breast cancer
A legfontosabb adatok
- Ki végzi
- Champalimaud Clinical Centre
- Hol
- Lisbon és Porto (Portugália)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2024. ápr. 17.
- Várható befejezés
- 2027. jan. 15.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2025. június 27.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek korai stádiumú, még nem kezelt, nem áttétes triplanegatív emlőrákjuk van, és a daganatban az immunsejtek (TIL) aránya legalább 10%. Két kemoterápiás kezelést hasonlít össze, amelyeket a műtét előtt pembrolizumabbal együtt adnak.
- Életkor
- 18 éves vagy idősebb
- Nem
- Bármely nemű személy részt vehet
- A betegség stádiuma
- Szövettanilag igazolt triplanegatív emlőrák, még nem kezelt, nincs távoli áttéte (M0). Daganatméret T1c-től T4-ig, a nyirokcsomó-érintettség N0-tól N2-ig, a mérettől függően. Jó általános állapot (ECOG 0 vagy 1), a szív pumpafunkciója (LVEF) legalább 50%, vagy legalább az intézmény alsó normálhatára.
- Korábbi kezelés
- A daganat miatt korábban nem kapott kezelést. Nem vehet részt, aki az elmúlt 12 hónapban kemoterápiát, célzott kezelést vagy sugárkezelést kapott, vagy korábban anti-PD-1, anti-PD-L1 vagy anti-PD-L2 szert kapott.
- Biomarker vagy leletérték
- A daganatba beszűrődött limfociták (sTIL) aránya legalább 10%, helyben igazolva. A szűréskor mintavétel kell a daganatból, és az első kezelési ciklus után még egy.
A részvétel fő kizáró okai
- Más invazív daganat az elmúlt 5 évben (egyes bőr- és méhnyakrákok kivételével)
- Donortól származó szerv- vagy szövetátültetés
- Ismert HIV-, hepatitis B- vagy aktív hepatitis C-fertőzés
- Az elmúlt 2 évben kezelést igénylő aktív autoimmun betegség
- Súlyos szívbetegség, vagy szteroidot igénylő múltbeli vagy jelenlegi tüdőgyulladás (pneumonitis)
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Be willing and able to provide written informed consent for the trial
- Male participants: A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 12 months after the last dose of cyclophosphamide or 6 months after last chemotherapy (whichever occurs last) and refrain from donating sperm during this period. Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 12 months after the last dose of cyclophosphamide or 6 months after last chemotherapy (whichever occurs last)
- Be a female or male participant who is at least 18 years of age on the day of signing informed consent
- Have locally histologically confirmed diagnosis of invasive carcinoma of the breast that is classified as TNBC, as defined by the most recent ASCO/CAP guidelines
- Has locally confirmed tumor infiltrating lymphocytes (stromal) (sTILs) equal to or above 10%, as defined by the most recent International Guidelines on TIL Assessment in Breast Cancer
- Have previously untreated non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current AJCC staging criteria for breast cancer staging criteria as assessed by the investigator based on radiological and/or clinical assessment: a. T1c, N1-N2; b. T2, N0-N2; c. T3, N0-N2; d. T4a-d, N0-N2
- Provide a core needle biopsy consisting of at least 3 separate tumor cores from the primary tumor at screening to the designated central biobank (or responsible laboratories) and is willing to provide a second biopsy at the end of the first cycle of treatment
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days of treatment initiation
- Have left ventricular ejection fraction (LVEF) of ≥50% or ≥ institution lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening
- Have adequate organ function as defined in Table 2 of this protocol. Specimens must be collected within 28 days prior to the start of study intervention
Ki nem vehet részt
- Has had an allogenic tissue/solid organ transplant
- Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
- Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- If surgery was performed prior to screening, has persistent adverse events or incomplete wound healing considered clinically relevant by the treating investigator
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 12 months after the last dose of cyclophosphamide or 6 months after last chemotherapy (whichever occurs last)
- Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has significant cardiovascular disease, such as: a. History of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; b. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA class III or IV
- Has a known history of Human Immunodeficiency Virus (HIV) infection
- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
- Has a known history of active TB (Bacillus Tuberculosis)
- Has an active infection requiring systemic therapy
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant‘s participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 4 weeks of the first dose of treatment in this current trial
- Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial and to consent
Ez a vizsgálat jelenleg itt érhető el: Portugália.
- Centro Hospitalar Universitario De Lisboa Norte E.P.E.Lisbon, PortugáliaRésztvevőt keres
- Champalimaud Clinical CentreLisbon, PortugáliaRésztvevőt keres
- Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E.Porto, PortugáliaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
1) To detect an immunologic activation signal and the immunologically defined most suitable patient population for the synergistic interaction between pembrolizumab and chemotherapy backbone, as assessed by precursor exhausted- and terminally differentiated exhausted T cell subpopulations and transcriptional changes of T cell populations infiltrating tumors at baseline and C2D1 in subjects with TNBC with TILs ≥ 10%. 2) To evaluate the rate of pCR in subjects with locally advanced TNBC with TILs ≥ 10%
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Immunogenicity Profile of Neoadjuvant Keytruda in Combination with Anthracycline versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR (KeyPARTNER)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
- A regiszteradat frissítve
- 2025. június 27.